Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: a retrospective study

Although being active in terms of ORR, bevacizumab plus microtubule targeting agents - mainly taxanes - leads to a high rate of gastro-intestinal perforations and fistula in heavily pre-treated ovarian carcinoma patients.